What You Should Know
- The Deal: Academic publishing giant Wiley is licensing a massive portfolio of its scientific and medical content to OpenEvidence, the clinical AI platform used by more than 40% of U.S. physicians.
- The Assets: The integration brings high-value, peer-reviewed literature directly into the AI’s evidence layer. This includes the prestigious Cochrane Database of Systematic Reviews (the gold standard for clinical guidelines), Cochrane Clinical Answers, and over 400 Wiley journals and textbooks spanning oncology, neurology, cardiology, and more.
- The Problem: We are living through a paradox. Global medical knowledge currently doubles every 73 days, yet it historically takes an average of 17 years for published research to translate into bedside clinical practice.
- The “Gold In, Gold Out” Philosophy: General large language models (LLMs) hallucinate because they are trained on the open internet. OpenEvidence (which recently reached a staggering $12 billion valuation) trains specialized models exclusively on peer-reviewed literature, ensuring every generated answer is grounded, cited, and verifiable.
- Wiley’s Strategy: Rather than attempting to build a standalone, walled-off clinical AI to compete with tech startups, Wiley is actively integrating its trusted scientific knowledge into the platforms where physicians are already making decisions.
